Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: BTK Inhibitors in RA

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: BTK Inhibitors in RA

Summary

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics-

- Awareness and potential of BTK inhibitors in RA

- Perceptions of BMS-986142's Phase IItrial design

- Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA

Key Highlights

- Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data

- KOLs were divided over BMS-986142's ability to achieve ACR70 by Week 12 in a refractory patient population

- For the majority of KOLs, poseltinib's discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

BTK inhibitors, rheumatoid arthritis, Phase II, trial design


Companies

BMS

Lilly

Roche

Merck

AbbVie

Company Profile

Company Profile Title

KOL Perspectives: BTK Inhibitors in RA

Summary

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics-

- Awareness and potential of BTK inhibitors in RA

- Perceptions of BMS-986142's Phase IItrial design

- Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA

Key Highlights

- Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data

- KOLs were divided over BMS-986142's ability to achieve ACR70 by Week 12 in a refractory patient population

- For the majority of KOLs, poseltinib's discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

BTK inhibitors, rheumatoid arthritis, Phase II, trial design


Companies

BMS

Lilly

Roche

Merck

AbbVie